Lantheus Holdings, Inc.

LNTH

$4.24B

Mid Cap

NASDAQIn Vitro & In Vivo Diagnostic Substances🇺🇸North AmericaNORTH BILLERICA808 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 29, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

🎯PDUFANext

FDA PDUFA Date LNTH-2501 (priority review)

3/29/2026

Next-generation PSMA imaging agent for prostate cancer detection. For Prostate cancer imaging.

Source

🎯PDUFA

FDA PDUFA Date product name (priority)

5/6/2026

For certain type of cancer. NDA filing. Extracted from SEC filing: 8-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

DEFINITY

Phase 3

Cardiac Disease

DEFINITY®

Phase 3

Cardiac Disease

Flurpiridaz F18

Phase 3

Coronary Artery Disease

Sestamibi

Phase 3

Kawasaki Disease

Peflutren Lipid Microsphere Injectable Suspension

Phase 2

Liver Disease

BMS747158

Phase 2

Ischemia

Technetium Tc99m Sestamibi

Phase 2

Kawasaki Disease

Drug Name	Phase	Indication	Designations
DEFINITY	Phase 3	Cardiac Disease	-
DEFINITY®	Phase 3	Cardiac Disease	-
Flurpiridaz F18	Phase 3	Coronary Artery Disease	-
Sestamibi	Phase 3	Kawasaki Disease	-
Peflutren Lipid Microsphere Injectable Suspension	Phase 2	Liver Disease	-
BMS747158	Phase 2	Ischemia	-
Technetium Tc99m Sestamibi	Phase 2	Kawasaki Disease	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

LNTH News